T o discover genes that play an important role in cardiovascular disease, investigators have studied proteins that might be important in a disorder. If biochemical or physiological abnormalities were found, these investigators could work back to the gene that encoded the protein, thereby identifying the genetic mutations that caused the disorder. This approach has helped to advance our understanding of cardiovascular biology and disease. In particular, investigators have used this approach to make great progress in our understanding of abnormalities in lipoprotein and lipid metabolism.' Recently, investigators have taken a different and complementary approach to these problems, one that involves molecular genetics. Often referred to as "reverse genetics" or "positional cloning," this strategy begins with the chromosomal localization of a gene that is responsible for an inherited disorder. (Neither of these terms accurately describes the actual process of mapping a disease gene and ultimately identifying disease-causing mutations. The term "reverse genetics" does not reflect the process but rather the change in experimental direction from starting with proteins to beginning with genes. The term "positional cloning" is more accurate in that it implies the cloning of a gene on the basis of its chromosomal location. Merely cloning a gene located near a disease locus, however, does not prove that it is the disease gene. We prefer to use the term "mapping and mutational analysis" to describe the process of disease gene identification outlined here.) The ultimate goal of the approach is to define abnormalities in the protein product of the gene and explain the disease pathogenesis. The purpose of this article is to review the theory and practice of the first step in this genetic strategy, linkage analysis of families with inherited disease.
Genetic Basis of Linkage Analysis
In the late 19th century, Gregor Mendel demonstrated that traits were inherited as independent units; that is, the inheritance of one trait did not influence the likelihood of inheriting a second.2 This fundamental rule of inheritance is known as Mendel's law of independent assortment. In the early 1900's, Thomas Hunt Morgan and his coworkers proposed the existence of an exception to this law. In breeding experiments performed with Drosophila, these investigators noted that certain traits, or genes, were inherited together (coinherited) more frequently than would be predicted by chance.3'4 These coinherited genes were said to be linked. It later became apparent that genes were coinherited or linked because they were physically located on the same chromosome.5 Linkage analysis is a technique that can be used to identify genes that are coinherited and therefore are located on the same chromosomal segment.
Human cells contain 23 pairs of homologous chromosomes, for a total of 46 diploid chromosomes. An individual inherits one set of chromosomes from his mother and the other set from his father. Each chromosome consists of a linear array of double-stranded deoxyribonucleic acid (DNA); the entire genome consists of approximately 3 
DNA-Based Markers
The ideal genetic marker would be easily detectable and would exist in a number of different, or polymorphic, forms. Linkage between a marker and a disease gene is detectable only if the individual with the disease gene carries two different forms of that marker. Like genes, a marker has a specific chromosomal location or locus, and different forms of the same marker are also referred to as alleles. Thus, allelic forms of the same marker share the same chromosomal location. When an individual carries two different alleles of one marker locus, he is said to be heterozygous for that marker. If the alleles are identical, he is said to be homozygous.
Until recently, only a limited number of markers were available. Most of these were protein polymorphisms like blood group antigens or HLAs. Only about 30 of these protein polymorphisms were useful, and these represented only a few chromosomes and an even smaller portion of the human genome. For lack of genetic markers, most human inherited disorders could not be approached by use of linkage analysis.
The situation improved dramatically with the advent of recombinant DNA technology in the 1970s. In 1978, the University of Utah sponsored a genetics retreat at a ski resort in the Wasatch mountains. At that meeting, David Botstein, Ronald Davis, and Mark Skolnick first suggested that variations in DNA sequence, which were known to exist in other organisms, might also exist in humans. They further suggested that these variations could be detected by use of the tools of molecular biology and that they could be used as polymorphic markers in linkage studies.9 One year later, Kan and Dozy'0 demonstrated the existence of DNA sequence variation at the ,B-globin locus associated with sickle cell anemia. Shortly thereafter, DNA variation was also observed at the same locus in association with thalassemias.11 Thus, the /3-globin gene was the first DNA-based polymorphic marker. In 1980, Ray White and his colleagues identified the first highly polymorphic locus in an arbitrary, noncoding stretch of DNA (Wyman and White12).
Restriction Fragment Length Polymorphisms
The new strategy has proved to be very powerful. Human DNA sequences contain a high level of variation; for example, differences in sequence exist between homologous chromosomes at every 200-300 base pairs. The initial problem was how to detect them. One way to detect sequence polymorphisms is with restriction enzymes. A restriction enzyme, produced by and purified from certain bacteria, recognizes a specific sequence in a linear piece of double-stranded DNA called a restriction site, where it cleaves the DNA. Variations in DNA sequence that create or eliminate a restriction site will result in a change in the length of the resultant restriction fragment (Figure 2A ). These sequence variations became known as restriction fragment length polymorphisms (RFLPs). Figure 4 had a homozygous genotype (a genotype of 1,1) at this marker locus, all of his children would be expected to inherit one copy of that allele ( Figure 4B ). In this example, both affected and normal children would inherit one copy of the 1 allele, and the marker would be uninformative for linkage.
Markers for Variable Number of Tandem Repeats
Fortunately, another kind of DNA marker exists, one that detects many different polymorphic forms in the general population. Human DNA contains sequences that are tandemly repeated throughout the genome ( Figure 2B ; References 14 and 15). The function of these tandem repeats is uncertain, but the number of repeats is highly variable, and these variations can be detected. The vast majority of these sequence variations are stably inherited (that is, they do not mutate with high frequency), so they can be used for linkage analysis. Probes for markers based on the variable number of tandem repeats (VNTRs) will detect a large number of variations in the general population, greatly increasing the likelihood that individuals in a family will be heterozygous, thereby increasing the informativeness of the marker for linkage. Like RFLPs, VNTRs can be detected by use of restriction enzymes in a technique similar to the one described above ( Figure 3 ).
Polymerase Chain Reaction-Based Markers
Recently, a number of different types of repeated units have been identified in human genomic sequences ( Figure 2C ; References [16] [17] [18] . As with VNTRs, the function of these repeated sequences is uncertain, but they can be used for linkage analyses if the polymorphic forms can be detected. In general, however, these repeated sequences are too small (for example, two base-pair, or dinucleotide, repeats like CA repeats) to be detected by a strategy that uses restriction enzymes. However, these small repeated sequences can be detected by use of a recent technical advance, the polymerase chain reaction (PCR; Figure 5 ). In PCR, a double-stranded piece of DNA is denatured and then enzymatically copied, or amplified. After one round of amplification, the result is a net doubling of DNA. If the process is repeated through multiple cycles of amplification, multiple copies of DNA will result. Thus, PCR is an enzymatic DNA copying machine.
PCR specificity is in part dependent on the starting material, or template DNA. In the experiments described here, template DNA is usually human genomic DNA that contains two double-stranded copies of every locus in the genome. A second critical factor for PCR specificity results from the sequence of small synthetic pieces of DNA of approximately 20 nucleotides called oligonucleotide primers. Like probe DNA, a primer is designed to be complementary to a specific DNA sequence in the template DNA. In general, two different primers (a primer pair) that flank a specific locus of interest are used in each PCR reaction. When the template and primer pair are denatured and then cooled, the primers will bind to complementary sequences on the template. The enzyme, or polymerase, that copies DNA in PCR reactions is primer-dependent; that is, the polymerase will copy only the specific sequences that are adjacent to the primer. Furthermore, the polymerase is unidirectional; that is, it will copy adjacent sequences only from the 5' to the 3' direction.
A. RFLP interest, PCR will amplify both, and two different amplification products will result. These two different products can then be distinguished by SSCP or DGGE. The principle underlying SSCP is that during electrophoresis, a single strand of DNA will migrate through a nondenaturing gel at a rate that depends on the size and the specific sequence of the strand. Another strand of the same size containing a single nucleotide substitution or other sequence polymorphism will, under certain electrophoretic conditions, travel through the same gel at a slightly different rate, presumably because of conformation differences. In DGGE, by contrast, double-stranded DNA fragments are separated by electrophoresis through a gel that contains an increasing gradient of denaturant. As the DNA passes through the gel, it eventually reaches a concentration of denaturant that will convert the DNA from the doublestranded to the single-stranded form, dramatically changing the mobility of the fragments. The Figure 7 .
The task of generating a complete linkage map of the human genome is far from completion; by examining Figure 7, 
Families
The first step in linkage analysis is to identify a suitable family. We were fortunate in having access to the largest single family with LQT that has been described (Figure 8 ). This family has been followed and carefully characterized for many years by Michael Vincent and Katherine Timothy of the LDS Hospital in Salt Lake City, Utah.33-37 The story of this family begins in the mid 1800s, when the two brothers shown in the second generation of Figure 8 emigrated from Denmark to a small town in Utah. We do not know much about their health except that they were excluded from the family profession of fishing for health reasons. Nevertheless, they fathered the offspring shown in Figure 8 . As one can see in the figure, the LQT Figure 9 shows the spectrum of corrected QT interval (QT,; Reference 38) asymptomatic individuals with a QT, of 0.47 second or greater were classified as affected.39 All family members that did not meet these diagnostic criteria were classified as uncertain. As a result, the family was divided into three approximately equal groups.
Genotypic Characterization
The third step in linkage analysis is genotyping, a process that is outlined in Figure 3 . DNA extracted from the leukocytes of each family member is incubated with a restriction enzyme. The resultant restriction fragments are separated by agarose gel electrophoresis and transferred to nylon filters. These filters are then incubated with a DNA marker that detects RFLPs in the general population. The pattern of RFLPs for each individual in the study is entered into a computer relational data base that interfaces with the LINKAGE programs. [40] [41] [42] [43] These programs analyze the phenotypes and genotypes of individuals in the family and calculate the odds that a DNA marker and the disease gene are linked. The odds are presented in a logarithmic form called the LOD score (LOD is an acronym for the logarithm of the odds). A LOD score of +3 (odds of 1,000/1) is considered to be good evidence for linkage. A LOD score of -2 (odds of 1/100) effectively excludes linkage at a given locus. Before linkage analysis can begin in full, the existence of misinheritances in the family must be excluded. As false paternity occurs with a fairly high frequency in the general population, this is an important step. The best DNA markers for establishing inheritance in a pedigree are those that are highly polymorphic and thus likely to be informative. As mentioned earlier, one group of very highly polymorphic markers detects VNTRs. It is not unusual for VNTR markers to detect more than 10 polymorphisms in the general population. An example of a misinheritance detected by a VNTR marker is shown in Figure 10 .
Once we had resolved all misinheritances in the family, we were able to begin general linkage analysis.
As we had few other physiological clues and no data about the chromosomal location of the LQT locus, we began our study with highly polymorphic markers on chromosome 1 and worked our way to chromosome 22. In the process, LOD scores of more than +2 (odds favoring linkage of more than 100/1) were identified with two different markers. Although tantalizing, these scores proved to be the result of chance, because the scores did not improve when adjacent markers were tested. As linkage was not identified in our first series of experiments, we began to test additional markers from untested chromosomal regions until linkage was finally identified (Figure 7) . In the process, we successfully scored more than 245 markers and excluded approximately 60% of the human genome. Linkage was identified using the Harvey ras-1 (H-ras-1) gene as a marker38; this marker detects a VNTR polymorphism located on the short arm of chromosome 11 (chromosome llp; References 44 and 45). The LOD score was + 16.43, indicating that the odds favoring linkage were greater than 1016/1.
Genetic Distance
As mentioned above, genetic recombination complicates linkage analysis and certainly increased the complexity of our study. Recombination frequencies, however, can be converted to genetic map distances using specific mapping functions that take into account undetected double-crossover events. For example, if recombination between two loci occurs with a frequency of 1%, the loci are said to be separated by a genetic distance of 1 centimorgan (cM). If, on the other hand, the recombination frequency is 20%, the map distance is approximately 26 cM (the relation between map distance and recombination fraction is not linear at high recombination frequencies because of the frequency of double recombinants). On average, 1 cM corresponds to a physical distance of about 1 million base pairs of DNA. In our study, no recombination was observed between the disease locus and H-ras-1. Thus, the maximum LOD score (Table 1 ) was identified at a recombination fraction of zero. 39 If, however, the data showed recombination between the two loci, the computer would have calculated a maximum LOD score at a specific recombination fraction, or theta (0). As no recombination was observed between LQT and H-ras-1, these loci are tightly linked in genetic terms and are likely to be in close physical approximation (probably within 3 million to 6 million base pairs).
On the basis of the complete linkage between H-ras-1 and LQT, this proto-oncogene became a candidate gene for the disorder. This hypothesis was especially exciting because a physiological rationale for the involvement of ras in LQT exists. Recent experiments done in a cellfree system have shown that ras proteins and GAP, the GTPase activating protein, can regulate atrial potassium channels. 46 tients (unpublished observations). On the basis of these data, we cannot be definitive about the candidacy of H-ras-1 in LQT. As will be described in more detail below, many other candidate genes for LQT are likely to reside in this chromosomal subunit, and each must be considered until the disease gene is identified.
Locus Homogeneity
As a result of these linkage studies, genetic diagnosis of LQT for members of the family shown in Figure 8 is secure. Can these markers be used to diagnose LQT in other families? In the six additional and unrelated LQT families studied to date, the answer is yes.47 One of these secondary families is shown in Figure 11 . The genotypes for each individual using the H-ras-1 gene as a VNTR marker are also shown. In the families studied, nine alleles were observed at this locus, and they are numbered 1-9. Focusing on the lower left section of the pedigree in Figure 11 , one can see that the unaffected father is homozygous at the H-ras-1 locus with a 4,4 genotype. The phenotypically affected mother, on the other hand, is heterozygous at ras with alleles 3 and 8.
All of the children should inherit the 4 allele from their father and either the 3 or the 8 allele from the affected mother. As one can see, all the affected children inherited the 8 allele from their mother, whereas normal children inherited the 3 allele. In the rest of the family, every affected individual inherited the 8 allele, indicating that in this family, like the original family studied, LQT is probably linked to loci on the short arm of chromosome 11. The combined LOD score for the six additional families was 5.25, indicating that the odds favoring linkage were greater than 105/1. Again, the maximum LOD score was at a recombination fraction of zero, indicating that no recombinants would exist in any of these families. Thus, the H-ras-1 marker can be used in these families for presymptomatic diagnosis of LQT.
Limitations of Linkage Analysis
Although linkage analysis using recombinant DNA technology is quite powerful, it has limitations. It is possible, for example, that mutations at several different genetic loci cause a phenotype that is similar to LQT. Locus heterogeneity for other disorders, such as hypertrophic cardiomyopathy48-50 and the Marfan syndrome,51 has been described, and it would not be surprising to learn that LQT is similar. In that event, markers on chromosome llpl5.5 would not be useful for genotypic diagnosis in unlinked families.
Even if the majority of LQT proves to be a result of mutations in one gene, linkage analysis cannot be used to determine the gene-carrier status of individuals in very small families or in sporadic cases. In Figure 11 , linkage between the marker and the disease gene was suggested because the disease phenotype always cosegregated with a specific genotype (the 8 allele) in this large family. Multiple meioses were scored in several generations, and marker informativeness was good (affected parents were heterozygous). In a smaller family ( Figure 12A ) or in a sporadic case ( Figure 12B ), it may not be possible to establish linkage, even if the marker is highly polymorphic and very tightly linked to the disorder. In the small family shown in Figure 12A , identification of linkage is not possible because there are not enough meiotic events available for a statistically significant LOD score to be established. In the 
Identification of Disease Genes by Mapping and

Mutational Analysis
The obvious concern that one has when initiating a linkage study is that linkage will not be identified. As DNA markers and linkage maps continue to improve, such concerns will be minimized, and continued improvement will be limited by the availability of families and phenotyping difficulties. Once linkage between a DNA marker of known chromosomal location and an inherited disease has been clearly identified, the focus turns to identification of the disease gene, and a number of strategies become possible. With luck, a gene that was previously mapped to the same chromosomal segment will become a candidate for the disease gene because of its chromosomal location and the feasibility of its involvement in the disorder. Frequently, however, no reasonable candidate gene is apparent, and a different, much more labor-intensive approach must be taken. In general, primary linkage analysis localizes a disease gene to a DNA segment of approximately 4 million to 10 million bases on either side of the linked marker. This DNA segment may contain hundreds of genes, most of which have yet to be identified and characterized. To identify the disease gene in such a large sea of nucleotides can be daunting, but it can be done. The general strategy that can be used has been referred to as "reverse genetics" or "positional cloning," but we generally use the phrase "mapping and mutational analysis" because it more clearly defines the process. The first step is to confine the disease gene to a chromosomal segment of about 1 million base pairs. This can be done by a combination of refined linkage and physical mapping. To improve the linkage map, one must identify new polymorphic markers that are very tightly linked to, but are recombinant with, the disease phenotype in families. These markers are called flanking markers and can be identified from cloned DNA segments from the region of interest. As the goal is to identify linked markers that recombine with the disease phenotype, it is very helpful to identify and characterize new extended families with the disorder. Another localizing method that has proved very helpful for disease gene identification is the identification of chromosomal anomalies like translocation and small deletions that are associated with the disease. If such an anomaly exists in Once the disease gene has been confined between flanking markers to a chromosomal segment of about 1 million base pairs, the identification of genes that will be candidates for the disease gene solely on the basis of their location becomes feasible. First, the DNA that 
